Massive study tracks breast cancer care in china to improve future treatments
NCT ID NCT07476170
First seen Mar 27, 2026 · Last updated May 20, 2026 · Updated 7 times
Summary
This study is collecting information from medical records of 14,000 people in China with a common type of advanced breast cancer (HR+/HER2-). The goal is to see which treatments doctors are actually using and how well they work in everyday practice, especially newer drugs like CDK4/6 inhibitors. No new treatments are being tested—researchers are just observing what happens to patients over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative SIte
RECRUITINGBingjie, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.